ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WaveSeeker who wrote (117)	12/9/1998 8:44:00 PM
From: Haolin Ni	Read Replies (3) of 1084

Caution to any one intends to buy ASTM in the morning!!!!!!!!!! (from company profile) For the fiscal year ended 6/98, revenues ( of ASTM) fell 34% to $249 thousand. Net loss applicable to Common rose 47% to $21 million. Results reflect the end of research agreement with Rhone-Poulenc Rorer, $3.4 million related to the sale of preferred stock and increased development activities. ASTM has only 11.2 million cash in hand. Therefore, company has to get new money to keep its live by sell new shares or sell something else. The news about its research development will bring no profit for the company in years. Please read the charts of GERN and ENMD, which show you the risk to buy biotech company after news. The longs are plan to sell the shares and shorts want to make profit from ASTM as well. My friends and I have set the orders to short ASTM as we did in ENMD and GERN. GOOD LUCK!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next